氟卡胺(Flecainide Acetate)是70年代由美国合成的新型抗心律失常药物,属于Ic类钠离子通道阻滞剂[1]。1980年后欧美已用于临床治疗快速性心律失常,取得了较满意疗效。近年动物实验和临床观察结果表明,本药有口服吸收完全,可静脉给药,半衰期长及严重副作用少,可长期用于治疗严重室性心律失常等优点,可能成为有发展前途的抗心律失常药[2]。 Flecainide acetate (Flecainide Acetate) is a novel anti-arrhythmic drug synthesized by the United States in the 1970s, belonging to class Ic sodium channel blockers [1]. After 1980, Europe and the United States have been used to clinical treatment of tachyarrhythmia, and achieved more satisfactory results. Recent animal experiments and clinical observations show that the drug has oral absorption completely, intravenous administration, long half-life and serious side effects, can be used for long-term treatment of severe ventricular arrhythmias, etc., may be promising anti-arrhythmia Medicine [2].